Evidence map›Paper›PMID 34480360›Full record

Observational studyTransfusion2021

Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.

Johanne Rozema, Eric N van Roon, Robby E Kibbelaar, Nic J G M Veeger, Christiaan L Slim, Harry de Wit, Mels Hoogendoorn, on behalf of the HemoBase Population Registry Consortium

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Transfusion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Johanne RozemaUnit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-9454-8637
Eric N van RoonUnit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.
Robby E KibbelaarDepartment of Pathology, Pathology Friesland, Leeuwarden, The Netherlands.
Nic J G M VeegerScience Bureau Department, Science Bureau, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
Christiaan L SlimLocation Medical Center Leeuwarden, Certe Medical Diagnostics & Advice, Leeuwarden, The Netherlands.
Harry de WitLocation Medical Center Leeuwarden, Certe Medical Diagnostics & Advice, Leeuwarden, The Netherlands.
Mels HoogendoornDepartment of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
on behalf of the HemoBase Population Registry Consortium
Medisch Centrum Leeuwarden · NLUniversity of Groningen · NLFriesland College · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIneffective hematopoiesis in patients with myelodysplastic syndromes (MDS) often results in transfusion dependence. The burden of frequent transfusions in the real-world MDS population is largely unknown. STUDY DESIGN AND

methodsAn observational, retrospective, population-based study, using the HemoBase registry, was performed including all patients diagnosed with MDS between 2005 and 2017 in Friesland, a province in the Netherlands with approximately 650,000 inhabitants. Detailed clinical information was collected from the electronic health records. Transfusion burden was classified according to the International Working Group 2018 criteria: not transfusion dependent, low (LTB), or high transfusion burden (HTB). Univariate and multivariable regression analyses were performed.

resultsOf 292 patients, 136 (46.6%) had a HTB of ≥8 units/16 weeks and 17 (5.8%) had a LTB of 3-7 units/16 weeks. This was present in all types of MDS patients, but patients aged 75-84 years (odds ratio [OR] 4.02, 95% confidence interval [CI]: 1.84-8.82), high-risk MDS patients (OR 2.88, 95% CI: 1.08-7.68) and MDS-EB-2 patients (OR 7.07, 95% CI: 2.17-22.90) were particularly at risk for a HTB. DISCUSSION: This study provides a reliable estimate of the transfusion burden in real-world MDS patients, with almost half of the patients having a HTB. A HTB was observed in all MDS subtypes and both low- and high-risk MDS. Therefore, we conclude that the entire MDS population might benefit from novel agents that reduce the transfusion need and that might have beneficial effects on patient outcomes and healthcare utilization outcomes.

Indexed as

Blood TransfusionAgedAged, 80 and overFemaleHumansMaleMyelodysplastic SyndromesNetherlandsRegistriesRetrospective Studiesblood transfusionmyelodysplastic syndromespopulation-basedtransfusion dependence

Identifiers

PMID34480360
PMCPMC9293228
OpenAlexW3197769682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.